Upgrades Underperform Neutral X

FATE Fate Therapeutics

BofA Securities

Resumed Equal Weight X

FATE Fate Therapeutics

Wells Fargo

$6

Downgrades Buy Neutral X

FATE Fate Therapeutics

H.C. Wainwright

$115 $7

Downgrades Outperform Mkt Perform X

FATE Fate Therapeutics

BMO Capital Markets

$20 $7

Downgrades Buy Underperform X

FATE Fate Therapeutics

BofA Securities

$72 $4

Downgrades Outperform Mkt Perform X

FATE Fate Therapeutics

Cowen

Downgrades Overweight Neutral X

FATE Fate Therapeutics

Piper Sandler

$71 $12

Downgrades Buy Hold X

FATE Fate Therapeutics

Stifel

$107 $5.30

Downgrades Buy Hold X

FATE Fate Therapeutics

Truist

$46 $7

Downgrades Outperform Neutral X

FATE Fate Therapeutics

Wedbush

$42 $7

Downgrades Buy Neutral X

FATE Fate Therapeutics

Guggenheim

Downgrades Outperform Perform X

FATE Fate Therapeutics

Oppenheimer

Initiated Sell X

FATE Fate Therapeutics

Goldman

$10

Resumed Overweight X

FATE Fate Therapeutics

Cantor Fitzgerald

$98 $45

Initiated Buy X

FATE Fate Therapeutics

Canaccord Genuity

$42

Resumed Overweight X

FATE Fate Therapeutics

Wells Fargo

$90

Initiated Hold X

FATE Fate Therapeutics

Needham

Upgrades Mkt Perform Outperform X

FATE Fate Therapeutics

BMO Capital Markets

$50 $47

Initiated Neutral X

FATE Fate Therapeutics

Robert W. Baird

$28

Resumed Market Perform X

FATE Fate Therapeutics

BMO Capital Markets

$50

Upgrades Neutral Outperform X

FATE Fate Therapeutics

Wedbush

Initiated Outperform X

FATE Fate Therapeutics

Cowen

Upgrades Neutral Buy X

FATE Fate Therapeutics

Citigroup

$94 $87

Upgrades Neutral Buy X

FATE Fate Therapeutics

H.C. Wainwright

$120

Upgrades Neutral Outperform X

FATE Fate Therapeutics

Wedbush

$88

Resumed Buy X

FATE Fate Therapeutics

Jefferies

$145

Initiated Buy X

FATE Fate Therapeutics

BofA Securities

$115

Downgrades Outperform Neutral X

FATE Fate Therapeutics

Wedbush

Downgrades Buy Neutral X

FATE Fate Therapeutics

Citigroup

Resumed Neutral X

FATE Fate Therapeutics

H.C. Wainwright

$108

Initiated Buy X

FATE Fate Therapeutics

BTIG Research

$27

Initiated Overweight X

FATE Fate Therapeutics

Cantor Fitzgerald

Initiated Outperform X

FATE Fate Therapeutics

Oppenheimer

$27

Initiated Buy X

FATE Fate Therapeutics

Mizuho

Initiated Neutral X

FATE Fate Therapeutics

ROTH Capital

$20

Initiated Buy X

FATE Fate Therapeutics

Guggenheim

Resumed Buy X

FATE Fate Therapeutics

Citigroup

$26

Initiated Outperform X

FATE Fate Therapeutics

SVB Leerink

$20

Downgrades Overweight Eq-Weight X

FATE Fate Therapeutics

Stephens

Initiated Buy X

FATE Fate Therapeutics

Jefferies

Initiated Buy X

FATE Fate Therapeutics

Citigroup

$20

Downgrades Buy Neutral X

FATE Fate Therapeutics

H.C. Wainwright

$12

FATE  Fate Therapeutics, Inc.

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.